ArticleFuture oncology (London, England)2024

Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial.

Ehab L Atallah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.